Q3 2017 Earnings Estimate for Genomic Health, Inc. (NASDAQ:GHDX) Issued By Jefferies Group
Genomic Health, Inc. (NASDAQ:GHDX) – Research analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for shares of Genomic Health in a research report issued on Wednesday. Jefferies Group analyst B. Couillard now expects that the medical research company will earn $0.00 per share for the quarter, down from their previous estimate of $0.01. Jefferies Group has a “Hold” rating and a $33.00 price objective on the stock. Jefferies Group also issued estimates for Genomic Health’s FY2017 earnings at $0.01 EPS, Q1 2018 earnings at $0.06 EPS, Q2 2018 earnings at $0.06 EPS, Q4 2018 earnings at $0.07 EPS and FY2018 earnings at $0.26 EPS.
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Genomic Health had a negative return on equity of 4.44% and a negative net margin of 1.50%. The business had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. During the same period in the prior year, the business posted ($0.18) earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/05/q3-2017-earnings-estimate-for-genomic-health-inc-nasdaqghdx-issued-by-jefferies-group.html.
Other analysts have also recently issued reports about the stock. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday. Piper Jaffray Companies reiterated a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a research note on Thursday. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Raymond James Financial, Inc. reiterated a “market perform” rating on shares of Genomic Health in a research note on Wednesday, May 3rd. They noted that the move was a valuation call. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Genomic Health currently has an average rating of “Hold” and an average target price of $32.43.
Genomic Health (NASDAQ:GHDX) opened at 30.51 on Thursday. The stock’s 50 day moving average is $32.69 and its 200 day moving average is $31.05. The company’s market capitalization is $1.05 billion. Genomic Health has a one year low of $25.66 and a one year high of $33.97.
Several institutional investors have recently modified their holdings of GHDX. Dubuque Bank & Trust Co. bought a new position in shares of Genomic Health during the first quarter worth approximately $142,000. SG Americas Securities LLC raised its position in shares of Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares during the last quarter. Legal & General Group Plc raised its position in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock worth $196,000 after buying an additional 2,038 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Genomic Health during the first quarter worth approximately $218,000. Finally, Stonebridge Capital Management Inc. bought a new position in shares of Genomic Health during the first quarter worth approximately $259,000. 89.59% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Phillip G. Febbo sold 3,174 shares of the stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Fred E. Cohen sold 8,250 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $30.68, for a total transaction of $253,110.00. Following the completion of the transaction, the director now directly owns 74,145 shares in the company, valued at approximately $2,274,768.60. The disclosure for this sale can be found here. Insiders sold a total of 62,642 shares of company stock worth $1,944,896 in the last three months. Insiders own 46.20% of the company’s stock.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.